Gernandt & Danielsson advises Pareto Securities in the IPO of SciBase Holding AB (publ)’s on Nasdaq First North
SciBase is a Swedish medical technology company founded in 1998 that has developed Nevisense, a point-of-care device for the accurate detection of malignant melanoma.
In connection with the listing an offering of 3,300,000 new shares, corresponding to approximately 40% of the shares and votes in SciBase Holding AB (publ), has been sold for gross proceeds of SEK 165 million. Should the over-allotment option issued to Pareto Securities from the company be fully exercised, the offering will comprise in total 3,795,000 new shares, corresponding to approximately 43% of the shares and votes in SciBase Holding AB (publ), for total gross proceeds of approximately SEK 190 million.
Pareto Securities is Sole Manager and Bookrunner in connection with the offering. Gernandt & Danielsson is legal advisor to Pareto Securities. Avanza is Selling Agent and Certified Adviser. Gernandt & Danielsson advises Pareto Securities with a team consisting of Partner Carl Westerberg, Senior Associate Leo Lee and Associate Erika Olofsson.